779 patents
Page 18 of 39
Utility
Aminopyrimidinyl Derivatives
6 Jan 22
Brian Stephen GERSTENBERGER, Wenhua JIAO, Manjinder Singh LALL, Ricardo LIRA, Mark Edward SCHNUTE
Filed: 30 Jun 21
Utility
Binding Molecules to the Human OX40 Receptor
6 Jan 22
The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
Jing MIN, Yanli WU, Rory F. FINN, Barrett R. THIELE, Wei LIAO, Ronald P. GLADUE, Arvind RAJPAL, Timothy J. PARADIS, Peter BRAMS, Brigitte DEVAUX, Yi WU, Kristopher TOY, Heidi N. LEBLANC, Haichun HUANG
Filed: 13 Jul 21
Utility
Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
4 Jan 22
Mark Reynolds, Charles Todd Eary, Stacey Spencer, Derrick Juengst, Bruno Hache, Yutong Jiang, Julia Haas, Steven W. Andrews
Filed: 18 May 17
Utility
Antibodies to Coagulation Factor Xia and Uses Thereof
30 Dec 21
In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided.
Thomas MIKITA, Lauren K. ELY, Huilan GAO, Yun KIM, Isaac J. RONDON, Tovo DAVID, Shaun R. COUGHLIN
Filed: 23 Jun 21
Reissue
Compositions relating to a mutant
28 Dec 21
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B.
Maninder K. Sidhu, Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
Filed: 18 Apr 19
Reissue
Compositions relating to a mutant
28 Dec 21
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B.
Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
Filed: 18 Apr 19
Utility
Compositions and methods relating to a mutant
28 Dec 21
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B.
Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
Filed: 5 Dec 19
Utility
Immunogenic Compositions for Use in Pneumococcal Vaccines
23 Dec 21
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates.
David Cooper, Kathrin Ute Jansen, Michael William Pride
Filed: 1 Sep 21
Utility
Dosage Regimen for TFPI Antagonists
23 Dec 21
Dosing regimens for the treatment of coagulation disorders using anti-TFPI antibodies are provided.
Tong Zhu, Steven Arkin, Matthew H. Cardinal, Chay Ngee Lim, Satyaprakash Nayak
Filed: 9 Oct 19
Utility
Anti-proliferative agents for treating PAH
21 Dec 21
Samit Kumar Bhattacharya, Douglas Carl Behenna, Kimberly O. Cameron, Ping Chen, John M. Curto, Kevin Daniel Freeman-Cook, Mehran Jalaie, Robert Steven Kania, Yajing Lian, Sajiv Krishnan Nair, Cynthia Louise Palmer, Martin Youngjin Pettersson, Eugene Yuanjin Rui, Matthew Sammons, Qingyi Yang, Liying Zhang
Filed: 15 Apr 20
Utility
Combination for Treating Cancer
16 Dec 21
Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased cytokine agonist, and an anti-androgen or a pharmaceutically acceptable salt thereof.
Christoffel Hendrik Boshoff, Rossano Cesari, Cristian Massacesi, Deborah Charych
Filed: 4 Nov 19
Utility
PYRROLO[2,3-D]PYRIMIDINE Tosylate Salt, Crystalline Form Thereof and Manufacturing Process and Intermediates Thereto
16 Dec 21
The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof.
Brian Matthew SAMAS, Yong TAO, Douglas James Critcher, David Sydney Bernard Daniels, Kevin Paul Girard, Gregory Scott Goeken, Peter Robert Rose
Filed: 21 Oct 19
Utility
Crystalline Forms of Lorlatinib Maleate
16 Dec 21
This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (lorlatinib) maleate.
Klimentina Dimitrova Pencheva
Filed: 1 Jul 21
Utility
Polymorph Form of a Monophosphate Hydrate Salt of a Known Tetrahydroisoquinoline Derivative
16 Dec 21
This invention relates to crystalline (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol monophosphate hydrate, and to compositions and therapeutic uses thereof.
Brian Samas, Wesley Clark
Filed: 20 Jan 20
Utility
Aminopyrimidinyl compounds
14 Dec 21
Andrew Fensome, Ariamala Gopalsamy, Brian S. Gerstenberger, Ivan Viktorovich Efremov, Zhao-Kui Wan, Betsy Pierce, Jean-Baptiste Telliez, John I. Trujillo, Liying Zhang, Li Xing, Eddine Saiah
Filed: 2 Jul 20
Utility
Dihydro-pyrrolo-pyridine derivatives
14 Dec 21
Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Christopher Ryan Butler, Adam Matthew Gilbert, Erik Alphie Lachapelle, Laura Ann McAllister, Daniel Paul Uccello, Lei Zhang
Filed: 14 Jun 18
Utility
Methods and Combination Therapy to Treat Biliary Tract Cancer
9 Dec 21
This invention relates to a method of treating biliary tract cancer by administering to a patient in need thereof, over a period of time, therapeutic agents comprising a MEK inhibitor or a pharmaceutically acceptable salt thereof, and a fluoropyrimidine-containing therapy, to a patient in need thereof.
Do-Youn Oh
Filed: 12 Feb 19
Utility
Protein Tyrosine Phosphatase Inhibitors
9 Dec 21
James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John Peter FISCHER, Ronald Jay HINKLIN, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
Filed: 17 Oct 19
Utility
Process for the Preparation of 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE
9 Dec 21
Charles Todd EARY, Stacey SPENCER, Zack CRANE, Katelyn CHANDO, Sylvie ASSELIN, Weidong LIU, Mike WELCH, Adam COOK, Gabrielle R. KOLAKOWSKI, Andrew T. METCALF, David A. MORENO, Tony P. TANG
Filed: 13 Aug 21
Utility
Process for preparing pneumococcal polysaccharide-protein conjugates
7 Dec 21
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described.
William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
Filed: 1 Aug 19